Barunseang Hospital Designates Medipost Stem Cell Research Cooperation Hospital
Oct 23, 2024
Barunseang Hospital (Hospital Director Seo Dong-won) announced on the 22nd that it was designated as a stem cell research cooperation hospital by Medipost, a leading company in the field of stem cell treatment and research.
In addition, Director Chung Gu-hwang (Orthopedic Surgeon) of the Joint Center gave a special lecture on actual Cartistem treatment and the progress of patients at the invitation of Medipost, and was appointed as an advisor for joint stem cell treatment.
Medipost is a manufacturer of knee cartilage treatment 'Cartistem', and Cartistem is an allogeneic umbilical cord blood-derived mesenchymal stem cell product used to treat cartilage defects in degenerative arthritis patients. It has been proven to be stable and effective in treating arthritis through many years of research and clinical practice, and it is known to be effective especially when combined with treatment in the case of the flexor correction, 'radical tibial fracture (HTO)'.
Director Chung Gu-hwang has been implementing the treatment for many years, and confirmed that Cartistem treatment on the inner cartilage of the knee damaged by the O-shaped leg is effective in correcting O-legged as well as regenerating knee cartilage. The treatment effect was demonstrated by the international journal `The Knee'SIC(E) research paper jointly conducted by Director Chung Gu-hwang and medical staff at Barunseang Hospital's Joint Center.
Director Chung Gu-hwang has a good prognosis for treatment when stem cells (catistem) are combined with proximal tibial osteotomy in patients with medial arthritis transformed into O legs. This treatment helps maintain one's healthy knees without artificial joints by regenerating damaged cartilage and eliminating pain"As a research cooperation and advisor to Medipost in the future, we will actively exchange for the results of stem cell research and further help improve the prognosis of arthritis treatment. "
In addition, Director Chung Gu-hwang (Orthopedic Surgeon) of the Joint Center gave a special lecture on actual Cartistem treatment and the progress of patients at the invitation of Medipost, and was appointed as an advisor for joint stem cell treatment.
Medipost is a manufacturer of knee cartilage treatment 'Cartistem', and Cartistem is an allogeneic umbilical cord blood-derived mesenchymal stem cell product used to treat cartilage defects in degenerative arthritis patients. It has been proven to be stable and effective in treating arthritis through many years of research and clinical practice, and it is known to be effective especially when combined with treatment in the case of the flexor correction, 'radical tibial fracture (HTO)'.
Director Chung Gu-hwang has been implementing the treatment for many years, and confirmed that Cartistem treatment on the inner cartilage of the knee damaged by the O-shaped leg is effective in correcting O-legged as well as regenerating knee cartilage. The treatment effect was demonstrated by the international journal `The Knee'SIC(E) research paper jointly conducted by Director Chung Gu-hwang and medical staff at Barunseang Hospital's Joint Center.
Director Chung Gu-hwang has a good prognosis for treatment when stem cells (catistem) are combined with proximal tibial osteotomy in patients with medial arthritis transformed into O legs. This treatment helps maintain one's healthy knees without artificial joints by regenerating damaged cartilage and eliminating pain"As a research cooperation and advisor to Medipost in the future, we will actively exchange for the results of stem cell research and further help improve the prognosis of arthritis treatment. "
|
bellho@sportschosun.com
